In a patient with myocardial infarction who also has heart failure, which therapy is commonly recommended?

• A. Beta-Blocker
• B. Calcium Channel Blocker
• C. Nitrates Only
• D. ACE Inhibitors

Answer: (A)

In this situation, starting a beta-blocker is most beneficial because it targets the harmful effects of excess sympathetic stimulation that follow a myocardial infarction and contribute to heart failure progression. By slowing the heart rate, lowering blood pressure, and reducing myocardial oxygen demand, beta-blockers help limit ongoing injury, decrease the risk of dangerous arrhythmias, and prevent adverse remodeling of the ventricle. In patients with LV systolic dysfunction after an MI, these drugs improve survival and reduce sudden death when begun after stabilization and advanced cautiously.

Nitrates can help with chest pain but don’t improve long-term mortality in this setting. Calcium channel blockers, particularly non-dihydropyridines, can reduce cardiac contractility and may worsen heart failure, so they aren’t the preferred choice here. ACE inhibitors also provide clear mortality and remodeling benefits after MI with heart failure and are usually used alongside beta-blockers, but the therapy most consistently emphasized as a mortality-reducing cornerstone is the beta-blocker.